Citations

Clear

9383 citation(s) found for "Thomas, PS".

Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes
Cholack, George , Mwangi, Raphael , Vodička, Prokop , Habermann, Thomas M., Hinder, Verena , Robinson, Dennis P. , Feldman, Andrew L., Witzig, T.E. , Villasboas, Jose C., Ansell, Stephen M., Wang, Yucai, Thompson, Carrie A. , Slager, Susan L., Maurer, Matthew, Novak, Anne J. , Cerhan, James R., Witzig, Thomas E. , Habermann, Thomas M. , Cholack, George A , Habermann, Thomas , Ansell, Stephen M , Wang, Yucai , Slager, Susan L , Maurer, Matthew , Novak, Anne J , Cerhan, James R , Feldman, Andrew L. , Ansell, Stephen M. , Link, Brian K. , Wang, Yucai , Slager, Susan L. , Cerhan, James R. , Vodicka, Prokop

Mayo Clinic

British Journal of Haematology | March 10, 2026 | Volume: 208 | Issue: 5 | Pages: 1631-1640

10.1111/bjh.70397 | PMID 41806244 Get It

Summary Family history of haematological malignancy (FHHM) reflects inherited susceptibility to non‐Hodgkin lymphoma (NHL), but its prognostic significance remains poorly understood. We used a cohort study of 1994 NHL patients to evaluate associations between FHHM and clinical outcomes across lymphoma subtypes. We estimated associations, adjusted for sex and lymphoma‐specific prognostic index, of self‐reported FHHM in a first‐degree relative with overall survival (OS), event‐free survival (EFS) and lymphoma‐specific survival (LSS) using multivariable Cox regression models and with failure to achieve EFS at 24 months (EFS24) using logistic regression. FHHM prevalence was 12.8%, and the median follow‐up among survivors was 12.0 years. FHHM was not associated with OS. In subtype‐specific analyses, FHHM was associated with inferior LSS (hazard ratio [HR] = 1.98, 95% confidence interval [CI] 1.11–3.53) in follicular lymphoma (FL); this association and the association with EFS24 failure strengthened among those treated with front‐line immunochemotherapy (EFS24 failure odds ratio = 2.57, 95% CI 1.08–5.99; LSS HR = 2.68, 95% CI 1.09–6.58). In mantle cell lymphoma, FHHM was associated with inferior EFS (HR = 1.70, 95% CI 1.02–2.85). Interaction testing did not demonstrate significant heterogeneity of FHHM effects by lymphoma subtype. FHHM may be associated with adverse outcomes in select NHL groups, particularly FL. These findings warrant further investigation of germline and environmental factors potentially contributing to more aggressive FLs.
Liver Metastasectomy in Anal Squamous Cell Carcinoma: The Mayo Clinic Experience
Takacs, Noah , O’Donnell, Conor D. J., Atwell, Thomas D. , Jin, Zhaohui, Jin, Zhaohui , O'Donnell, C. , O'Donnell, Conor D J , Tran, Nguyen , Atwell, Thomas, Jin, Zhaohui , Tran, Nguyen H. , Jethwa, Krishan R. , Starlinger, Patrick

Mayo Clinic

Current Oncology | March 10, 2026 | Volume: 33 | Issue: 3 | Pages: 157

10.3390/curroncol33030157 | PMID 41892185 Get It

Background: Metastatic squamous cell carcinoma of the anus (SCCA) carries a poor prognosis, with systemic therapy remaining the standard of care. While metastasis-directed therapy improves outcomes in select gastrointestinal malignancies, the role of liver-directed intervention in metastatic SCCA remains undefined. We evaluated clinicopathologic features and oncologic outcomes of patients with liver-limited metastatic SCCA treated with curative-intent hepatic local therapy at a tertiary academic center. Methods: We conducted a retrospective cohort study of adults with histologically confirmed SCCA and liver-only metastatic disease who underwent curative-intent hepatic resection or ablation at Mayo Clinic between 1993 and 2023. Patients with extrahepatic disease or incomplete records were excluded. Demographic, tumor, treatment, and outcomes data were abstracted from electronic medical records. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method. Prognostic factors were assessed using univariate Cox proportional hazards models. Results: Twenty-five patients met inclusion criteria. Median age was 56.7 years, and 92% were female. Most patients had metachronous metastases (76%), a single hepatic lesion (56%), and unilobar disease (76%). Pre-intervention systemic therapy was administered in 52% of patients, with radiographic complete or partial responses observed in all treated patients. Liver-directed therapy consisted of surgical resection in 80% and thermal ablation in 20%. Among surgical patients, 90% achieved microscopically negative margins. With a median follow-up of 22 months, disease recurrence occurred in 80% of patients, most commonly within the liver. Median DFS was 7.27 months. Median OS from the date of liver-directed therapy was 51.3 months. On univariate analysis, poorly differentiated tumor histology was associated with inferior OS (hazard ratio 4.67, p = 0.018). No other clinicopathologic variables were significantly associated with DFS or OS. Conclusions: In this single-institution experience, carefully selected patients with liver-limited metastatic SCCA undergoing curative-intent hepatic-directed therapy achieved prolonged overall survival, substantially exceeding historical outcomes with systemic therapy alone. Despite frequent recurrence, the observed median OS exceeding four years supports consideration of liver-directed therapy within a multidisciplinary framework for patients demonstrating favorable disease biology and response to systemic treatment. Prospective studies are needed to better define patient selection and optimal integration of local and systemic therapies in the modern treatment era.
Surgeon-patient Sex Concordance and Long-term Clinical Outcomes and Costs Following Common Surgeries
Thomas, Hannah S. , Satkunasivam, Raj , Coburn, Natalie, Wright, Frances C. , Salles, Arghavan, Riveros, Carlos , Titus, Renil S. , Velasquez, Eusebio Luna, Armstrong, Kathleen, Detsky, Allan S. , Wallis, Christopher J.D., Lin, Lauren, O’Connell, Clare , Coburn, Natalie, Salles, Arghavan , Heybati, Kiyan , Luckenbaugh, Amy N. , Mundra, Vatsala , Velásquez, Eusebio Jesús Luna , Armstrong, Kathleen , Jerath, Angela , Wallis, Christopher J.D.

Mayo Clinic

Annals of Surgery | March 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000007047 Get It

Objective: To evaluate the associations between surgeon-patient sex concordance, long-term clinical outcomes and healthcare costs. Background Data: Emerging data suggest surgeon-patient sex concordance may improve short-term outcomes, especially for female patients, yet its long-term effects remain unknown. Methods: We conducted a population-based retrospective cohort study of adults undergoing common surgeries in Ontario, Canada (2007-2019). Patients were followed for 90 and 365 days. Surgeon-patient sex concordance was categorized into four dyads. Multivariate generalized estimating equations clustered by procedure type evaluated composite and individual (complications, readmission, mortality) clinical outcomes and healthcare costs. Results: A total of 1,165,711 patients were included. Female patients treated by male surgeons, compared with female surgeons, were more likely to experience an adverse composite event (90 d: aOR 1.12, 95% CI 1.08–1.17, P <0.001; 365 d: aOR 1.09, 95% CI 1.05–1.14, P <0.001), with no association among male patients (90 d: aOR 1.00, 95% CI 0.94–1.05, P =0.89; 365 d: 0.99, 95% CI 0.92–1.07, P =0.87). Long-term total healthcare costs were greater for patients treated by male surgeons - an effect seen in both male patients (90 d: aRR 1.08, 95% CI 1.03-1.14, P =0.002 and 365 d: aRR 1.08, 95% CI 1.02-1.14, P =0.007) and female patients (90 d: aRR 1.10, 95% CI 1.05-1.14, P <0.001, 365 d: aRR 1.09, 95% CI 1.05-1.14, P <0.001). Conclusions: Surgeon-patient sex concordance was associated with improved long-term outcomes for female, but not male, patients, and female surgeons’ patients had lower healthcare costs. Given these benefits, further investigation into the mechanisms driving these outcomes is warranted.
Anatomical Localization–Based Analysis of Relapsed Secondary Central Nervous System Aggressive B‐Cell Lymphoma (R‐SCNSL)
Okcu, Izel, Wang, Yucai, Li, Z., White, Launia J. , Johnston, Patrick B., Paludo, Jonas, King, Rebecca L., Witzig, Thomas E., Habermann, Thomas M., Nowakowski, Grzegorz S. , Witzig, Thomas E. , Habermann, Thomas M. , Li, Zhuo , Wang, Yucai , Witzig, T.E. , Okcu, Izel , Wang, Yucai , Rosenthal, Allison C, Habermann, Thomas , Johnston, Patrick B. , Rosenthal, Allison , Paludo, Jonas , King, Rebecca L., Tun, Han W.

Mayo Clinic

Hematological Oncology | March 8, 2026 | Volume: 44 | Issue: 2 | Pages: No page available

10.1002/hon.70182 | PMID 41794414 Get It

ABSTRACT 162 patients with relapsed secondary central nervous system lymphoma (R‐SCNSL) (median age, 65 years; male, 59.9%) including central nervous system (CNS)‐only ( n = 120) and concomitant CNS/systemic relapse ( n = 42) were retrospectively analyzed. Overall, 21.9% of patients were classified as high risk according to the CNS International Prognostic Index (CNS‐IPI). Several biological and clinical features were significantly associated with leptomeningeal involvement, including double‐ or triple‐hit (DHL/THL) status, MYC rearrangement, negative BCL6 expression by IHC, bone marrow involvement, and concomitant R‐SCNSL. Multivariable analysis showed that leptomeningeal involvement independently predicted inferior OS and was associated with a 98% increase in the hazard of death compared with parenchymal relapse (HR = 1.98, 95% CI: 1.20–3.26, p = 0.008). Based on anatomical localization, R‐SCNSL was classified into four subtypes: parenchymal‐only involvement (parenchymal‐CNS [P‐CNS], 68/42%) and parenchymal involvement plus systemic relapse (parenchymal‐concomitant [P‐concomitant], 17/10.5%); and leptomeningeal with or without parenchymal involvement (leptomeningeal‐CNS [LM‐CNS], 52/32.1%) and leptomeningeal with systemic relapse (leptomeningeal‐concomitant [LM‐concomitant], 25/15.4%). This anatomical classification significantly impacted OS and PFS ( p < 0.001). Two‐year OS and PFS were 58.2% and 29.1% for P‐CNS, 32.4% and 17.7% for P‐concomitant, 22% and 13.9% for LM‐CNS, and 7.1% and 0% for LM‐concomitant, respectively. ASCT showed a trend toward improved survival among patients with a response (CR/PR) in a 4‐month landmark analysis. These findings support the clinical application of the anatomical classification in the management of R‐SCNSL.
Target Trial Emulation in Observational Research—Strengths, Limitations, and Methodological Considerations
Baumeister, Sebastian-Edgar, Leiva-Escobar, Ignacio , Demmer, Ryan, Holtfreter, Birte , Nolde, Michael , Baumeister, Sebastian E. , Demmer, Ryan T , Holtfreter, Birte , Nolde, Michael , Baumeister, Sebastian‐Edgar , Demmer, Ryan T. , Papapanou, Panos N , Kocher, Thomas

Mayo Clinic

Journal of Periodontal Research | March 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jre.70095 | PMID 41793097 Get It

ABSTRACT Cohort studies are vulnerable to confounding and time‐related biases. Recent advances emphasize the importance of emulating a hypothetical target trial to minimize several of these biases. The target trial framework is a critical tool for designing cohort studies. It requires explicit specification of protocol components: eligibility criteria, treatment strategies, outcomes, timing of follow‐up (time zero), and the causal contrast to be estimated. Critical to this framework is defining “time zero” when treatment assignment takes place and follow‐up begins, which prevents prevalent user and immortal time bias and ensures proper temporal sequencing of confounders, exposure, and outcome. By guiding design, data collection, and analysis, the target trial framework helps align observational studies with the principles of randomized trials, improving the validity and interpretability of their findings. While it cannot eliminate unmeasured confounding, this approach promotes transparent, bias‐conscious cohort design, minimizes time‐related bias, and supports more robust causal inference with observational data.
Normothermic Regional Perfusion: Why Isn't the Lactate Coming Down?
Cywes, Claire , Brown, Thomas E. , Aniskevich, Stephen , Croome, Kristopher P, Croome, Kristopher P. , Croome, Kris P , Aniskevich, Stephen

Mayo Clinic

Clinical Transplantation | March 8, 2026 | Volume: 40 | Issue: 3 | Pages: No page available

10.1111/ctr.70489 | PMID 41772939 Get It

ABSTRACT During normothermic regional perfusion (NRP), lactate is the most commonly used liver viability marker. Lactate production from pyruvate breakdown in erythrocytes is not suspended during pRBC storage. By transfusing blood at a variety of stored ages, variable amounts of lactate are added to the NRP circuit and may influence serial lactate measurements. Sixteen DCD donors undergoing NRP were enrolled in a prospective study. Samples were drawn from pRBC bags prior to use in the NRP circuit and were tested for lactate values. Lactate values of the NRP circuit perfusate were also assessed Q15 min. Lactate values of the pRBCs varied from 4.4 mmol/L to >20 mmol/L and were strongly correlated with the age of the stored blood ( r 2 = 0.74). Donors in which the pRBCs were > = 20‐days from expiration (Newer Blood group) had a significantly lower lactate at 60 min of NRP compared to donors in which pRBCs were <20 day from expiration (Older Blood group) (4.0±2.0 mg/dL vs. 6.3±2.3 mg/dL; p = 0.048). If the lactate is not decreasing as anticipated, transfusion of older pRBC should be entertained as one possible explanation. In cases where the liver seems acceptable for transplantation, additional lactate testing with longer time on NRP or sequential NRP/NMP should be considered in lieu of declining the liver outright.
Family History and Solar Insolation in Bipolar I Disorder
Bauer, M., Glenn, Tasha , Achtyes, E. D., Alda, M., Ağaoğlu, Esen , Altınbaş, Kürşat , Andreassen, O. A., Angelopoulos, E., Ardau, R., Aydin, Mehmet Zeki , Ayhan, Y., Baethge, Christopher , Bauer, Rita, Baune, B. T., Balaban, Ceylan, Becerra‐Palars, Claudia, Behere, A. P., Belete, Habte , Belete, Tilahun, Belizario, G. Okawa, Bellivier, F., Belmaker, R. H., Benedetti, F., Berk, M., Bersudsky, Y., Bicakci, Ş., Birabwa‐Oketcho, Harriet , Bjella, T. D., Brady, Conan , Cabrera, Jorge , Cappucciati, Marco , Castro, A. M. Paredes, Chen, W., Cheung, E. Y. W., Chiesa, S., Chanopoulou, Margarita, Cuomo, A., Dodd, S., Etain, B., Fagiolini, A., Fellendorf, F. T., Ferensztajn‐Rochowiak, Ewa , Fiedorowicz, J. G., Fountoulakis, K. N., Frye, M. A., Geoffroy, P. A., Gitlin, M. J., Gottlieb, J. F., Grof, Paul , Haarman, B.C.M., Harima, Hirohiko, Hasse‐Sousa, M., Henry, C., Hoffding, L., Houenou, J., Imbesi, M., Isometsä, E. T., Janno, Sven , Johnsen, S., Karakatsoulis, G. N., Kardell, Mathias, Kessing, L. V., Kim, S. J., Kot, T. L., Koval, M., Lafer, B., Landén, M., Larsen, E. R., Licht, R. W., Ludwig, V. M., Mackenzie, Alan, Madsen, H. Østergaard, Madsen, S. Alberte Kongstad A., Mahadevan, J., Mahardika, Agustine , Mahfoudh, K. Ben, Manchia, M., Marsh, W., Martiny, Klaus , Mashima, Y., McLoughlin, D. M., Meesters, A. N. R., Meesters, Ybe , Melle, I., Meza‐Urzúa, F., Michaelis, Elisabeth, Mok, Y. Ming, Monteith, Scott , Moorthy, Muthukumaran, Morken, G., Mosca, Enrica, Mozzhegorov, A. A., Munoz, R., Mythri, S. V., Nadella, R. K., Nakanotani, Takako, Nielsen, R. Ernst, O'Donovan, C., Omrani, Adel, Osher, Yamima , Pantovic‐Stefanovic, M., Pariwatcharakul, Pornjira, Petite, Joanne, Pilhatsch, M., Ruiz, Y. Pica, Pinna, M., Pompili, M., Porter, R., Quiroz, Danilo , Rabelo‐da‐Ponte, F. Diego, Ramesar, Raj , Rasgon, NL, Redahan, Maria, Reddy, M. S., Reif, A., Reininghaus, E. Z., Richards, J. Gringer, Rybakowski, J. K., Sathyaputri, Leela, Scippa, A. M., Simhandl, Christian , Smith, D., Smith, J., Stackhouse, P. W., Stein, D. J., Stilwell, Kellen, Su, K.‐P., Sulaiman, A. Hatim, Suominen, Kirsi, Tanra, A. J., Tatebayashi, Yoshitaka , Teh, W. Lin, Tondo, L., Torrent, C., Tuinstra, Daniel, Uchida, Takahito, Vaaler, A. E., Vieta, E., Viswanath, B., Volf, C., Yang, K‐J, Yalcinkaya, O. Kaan, Young, A. H., Zgueb, Yosra , Whybrow, P. C., Houenou, Josselin , Isometsä, Erkki , Licht, Rasmus Wentzer , Manchia, Mirko , Nielsen, René Ernst , Stein, Dan J. , Kessing, Lars Vedel , Young, Allan H. , Achtyes, Eric D. , Belete, T , Berk, Michael , Crowe, M , Fagiolini, Andrea , Frye, Mark , Grof, P , Kessing, L V , Kim, S J , Manchia, Mirko , McLoughlin, D M , Nadella, R K , Ouali, U , Pariwatcharakul, P , Pompili, M , Porter, R , Ritter, P , Rybakowski, Janusz K , Stein, Dan J , Strejilevich, S , Subramaniam, M , Vaaler, A E , Vieta, E , Yoldi-Negrete, M , Young, Allan H , Bauer, M., Alda, Martin , Altınbaş, Kürşat , Andreassen, Ole A. , Angelopoulos, Elias, Ardau, Raffaella , Aydin, M., Ayhan, Yavuz , Behere, Aniruddh Prakash, Belizário, Gabriel Okawa , Bellivier, Frank , Belmaker, Robert H. , Benedetti, Francesco , Berk, Michael , Bıçakcı, Şule , Bjella, Thomas , Castro, Angela Marianne Paredes , Cuomo, Alessandro, Dallaspezia, Sara , Desai, Pratikkumar Vrajeshbhai , Dodd, Seetal , Étain, Bruno , Fagiolini, Andrea , Fellendorf, F.T., Fiedorowicz, Jess G. , Fountoulakis, Konstantinos Ν. , Frye, Mark A. , Geoffroy, Pierre A. , Gitlin, Michael , González‐Pinto, Ana , Haarman, Bartholomeus C. M. , Hasse-Sousa, Mathias , Henry, Chantal , Høffding, Lone, Imbesi, Massimiliano, Ivković, Maja , Johnsen, Søren Paaske , Kapczinski, Flávio , Karakatsoulis, Grigorios N. , König, Barbara , Kunz, Maurício , Lafer, Beny , Landén, Mikael , Ludwig, Vera Miriam , López‐Jaramillo, Carlos , MacKenzie, A., Madsen, Helle Østergaard , Mahfoudh, K., Marsh, W., Martínez‐Cengotitabengoa, Mónica , Martini, Julia , Mashima, Yuki , Meesters, Alie N.R., Melle, Ingrid , Meza-Urzúa, Fátima, Mikoláš, Pavol , Mok, Yee Ming , Morken, Gunnar , Mozzhegorov, Anton A., Mythri, SV, C, O'Donovan, Ouali, Uta , Stefanovic, M. Pantovic, Pfennig, Andrea , Ruiz, Yolanda Pica, Pinna, Marco , Rabelo-Da-Ponte, F.D., Rasgon, Natalie , Ratta‐apha, Woraphat , Redahan, Maria, Reif, A., Reininghaus, EZ, Ritter, Philipp , Strejilevich, Sergio , Suominen, Kirsi, Teh, Wen Lin , Torrent, C., Vieta, Eduard , Viswanath, Biju , Yoldi‐Negrete, María , Young, A.H., Whybrow, Peter C.

Mayo Clinic

Acta Psychiatrica Scandinavica | March 8, 2026 | Volume: 153 | Issue: 4 | Pages: 270-278

10.1111/acps.70075 | PMID 41734899 Get It

ABSTRACT Background Sunlight has profound impacts on physical and mental health, beyond vision, including effects on circadian rhythms, alertness, mood, and sleep. A family history of any mood disorders is strongly associated with psychiatric disorders including bipolar disorder. The purpose of this study was to evaluate the association between a family history of any mood disorder in patients with bipolar I disorder and solar insolation at varied international onset locations. Methods Data for this analysis were available from 5842 patients with a diagnosis of bipolar I disorder obtained at 83 collection sites in both hemispheres. This included 4752 patients from 71 collection sites in the northern hemisphere and 1090 patients from 12 collection sites in the southern hemisphere. Patient data variables were obtained from records or interviews. Solar insolation data were obtained from The National Aeronautics and Space Administration (NASA) Power database for each onset location, and the ratio of the mean monthly minimum/mean monthly maximum solar insolation was calculated. Typically, the ratio is largest near the equator (little yearly change in solar insolation) and smallest near the poles (large yearly change in solar insolation). Results A significant relationship was found between a family history of any mood disorder, the ratio of the mean monthly minimum/mean monthly maximum solar insolation, and gender. The odds of a family history of mood disorder increased as patient location nears the poles and decreased near the equator. Female gender also increased the odds of having a family history of a mood disorder. Conclusions This study highlighted the association between family history, solar insolation, and gender in international patients with bipolar I disorder. Given the profound effects of sunlight on human health, the family of patients with bipolar disorder who live in the same location with the same solar insolation, and especially females, may be at increased risk for a mood disorder.
The CARE framework for AI dataset documentation in clinical laboratories: a comprehensive checklist and data lineage methodology
Garcia, Christopher A., Reed, Katelyn A. , Lantz, Eric, Day, Patrick L. , Stadler, Brian C, Zarella, Mark D. , Hart, Steven N. , Han, Wenchao, Wahsh, Ezzaddin Al, Novak, Debra, McClintock, David S. , Day, Patrick , Tavolara, Thomas E, Al Wahsh, Ezzaddin, Novak, Debra A, McClintock, David S , Hart, Steven N , Lantz, Eric, Han, Wenchao, Tavolara, Thomas Erol , Wahsh, EzzAddin Al, Novak, Debra A

Mayo Clinic

American Journal of Clinical Pathology | March 7, 2026 | Volume: 165 | Issue: 5 | Pages: No page available

10.1093/ajcp/aqag029 | PMID 42114029 Get It

Abstract Objectives Traditional laboratory regulatory frameworks provide robust guidance for conventional clinical testing but lack requirements for data documentation for artificial intelligence and machine learning (AI/ML) solutions. This gap creates significant risks since AI solutions directly inherit patterns, biases, and limitations from their training data. Here, we describe the development and implementation of a comprehensive data documentation checklist with accompanying data lineage for use within an AI lifecycle framework for clinical laboratories. Methods Building on the previously established Clinical AI Readiness Evaluator (CARE) framework, we developed a comprehensive data checklist and data lineage methodology through a multiphase process, including (1) comprehensive review of existing AI/ML data documentation frameworks, (2) focused meetings with 3 institutional AI operations teams, and (3) 3 rounds of iterative refinement by our multidisciplinary team. The checklist’s effectiveness was then assessed using 3 diverse AI/ML projects moving through the CARE framework. Results The CARE Data Checklist and Data Lineage provide a structured approach to documenting critical aspects of datasets used in AI/ML projects, including data composition, demographics, collection methods, labeling processes, usage constraints, maintenance requirements, and a data readiness assessment. The checklist addresses unique data-centric challenges of AI/ML applications, facilitating transparency, reproducibility, and regulatory compliance. Conclusions The CARE Data Checklist and Data Lineage serve as both a technical guide and a communication tool bridging gaps between technical and clinical stakeholders. By working on these documents early in the AI lifecycle, laboratories can anticipate and address data-related challenges, ultimately saving time, optimizing resources, and improving the reliability of AI-augmented laboratory solutions.
Gene Portals: A Framework for Integrating Clinical, Functional, and Structural Evidence into Rare Disease Variant Classification
Brünger, Tobias , Krey, Ilona , Kim, Suyeon, Klöckner, Chiara , Myers, Scott J, Johannesen, Katrine M. , Stefanski, Arthur , Taylor, Gary, Macnee, Marie , Dahl, Rebekka S., Yuan, Hongjie, Kim, Sukhan, Helbig, Ingo, Pan, Jen, Kurganov, Erkin , Baez, David, Zuberi, Sameer M., Lerche, Holger, May, Patrick, Ivaniuk, Alina, Meskis, Mary Anne , Hood, Veronica , Schust, Leah F., Freed, Amber, Froelich, Steven, Deng, Alexander T., Bouman, Arjan , Hajianpour, M.J. , Pal, Deb K. , Danvoye, Leslie, Lederer, Damien , BALCI, TUĞÇE, Hagebeuk, Eveline , Heidlebaugh, Alexis R. , Oetjens, Kathryn F., Striano, Pasquale, Williams, Sarah Drewes, Engelen, Kalene van , Howell, Katherine B. , Khoury, Jean , Benke, Tim A., Strehlow, Vincent , Platzer, Konrad, Ramsey, Amy J, Manaster, Lisa, Malepati, Sunitha, Fox, Pangkong M., Noebels, Jeffrey, Chung, Wendy, Poduri, Annapurna, Stripe, Laina Lusk, Ruggiero, Sarah M., Cohen, Stacey, Wilmarth, Olivia, Prentice, Anna Jenne, Cha, Esther, Budnik, Nikita , Kramer, Audra A. , Gh, Zhang, Palotie, Aarno, Daly, Mark J., Møller, R., Lemke, Johannes R., Lal, Dennis , Møller, Rikke S. , May, Patrick , Bruenger, Tobias , Pan, Jen Q , Farrant, Mark , Wyllie, David J A , Bosselmann, Christian , Mantegazza, Massimo , May, Patrick , Ivaniuk, Alina , Goodspeed, Kimberly , Trinidad, Marena , Aledo-Serrano, Ángel , Pal, Deb K , Platzer, Konrad , Ruggiero, Sarah M , Daly, Mark J. , George, Alfred L , Brunklaus, Andreas , Møller, Rikke S , Myers, Scott J. , Taylor, Gary, Pérez‐Palma, Eduardo , Schorge, Stéphanie , Dahl, Rebekka S. , Perszyk, Riley E. , Bajaj, Sunanjay , Helbig, Ingo , Wollmuth, Lonnie P. , Báez-Nieto, David , Zuberi, Sameer M. , Boßelmann, Christian M. , Mantegazza, Massimo , Cestèle, Sandrine , Ivaniuk, Alina , Kang, Jing‐Qiong , Gati, Cornelius , Montanucci, Ludovica , Wüster, Arthur , Deng, Alexander T. , Borovikov, Artem O. , Sharkov, Artem A. , Bouman, Arjan , Hoffman, Trevor L. , Howell, Katherine B. , Benke, Tim A. , Platzer, Konrad , Ramsey, Amy J. , Fox, Pangkong , Noebels, Jeffrey L. , Chung, Wendy K. , Poduri, Annapurna , Lusk, Laina G. , Cohen, Stacey , Smith, Lacey A. , Boesch, Sylvia , Prentice, Anna Jenne , Hommersom, Marina P. , Vanoye, Carlos G. , Nothnagel, Michael , Palotie, Aarno V. , George, Alfred L. , Zárate, Yuri A. , Brunklaus, Andreas , Traynelis, Stephen F. , Lemke, Johannes R.

Mayo Clinic

No container title available | March 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.05.26347086 | PMID 41822692 Get It

Abstract Rare Mendelian disorders affect 300-400 million people globally. Although genetic testing has become widely adopted, gene-specific evidence for tailored variant interpretation remains scattered across resources. We present Gene Portals, a framework for gene-centered multimodal knowledge bases that co-localize expert-harmonized clinical data, functional assays, population variation, structural annotations and gene-specific ACMG/AMP specifications within a single resource. A modular interface integrates this unified evidence with VCEP-refined ACMG specifications to enable automated gene-specific variant classification, infer molecular mechanisms, and support cross-gene analyses. We demonstrate the framework’s utility across five Gene portals spanning eleven neurodevelopmental disorder-associated genes, integrating data from 4,423 individuals with 2,838 unique variants, 36,149 ClinVar submissions, and 1,044 expert-curated molecular readouts. By organizing evidence that is otherwise dispersed across multiple sources into a unified, queryable framework, the SCN, GRIN, CACNA1A, SATB2 and SLC6A1 Gene Portals became widely used community resources and provide an extensible template for standardized rare-disease variant interpretation and mechanism-aware discovery.